Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Cambrex announced that it has opened a new 120m2 quality control (QC) laboratory at its site in Paullo, Milan, Italy.
read more
Cambrex has completed a new 600 m2 facility at its site in Karlskoga, Sweden, which incorporates new laboratories for process and analytical development.
read more
Wednesday, April 13, 2022
Cambrex announced the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility.
read more
Cambrex announced that it has completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA.
read more
Monday, September 05, 2022
Cambrex announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina
read more
Wednesday, October 14, 2020
Cambrex announced the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.
read more
Wednesday, April 08, 2020
Cambrex has completed an expansion of its biopharmaceutical analysis capabilities at the Durham, North Carolina site.
read more
Cambrex has completed the expansion of a new 150m2 research and development laboratory at its site in Paullo, Milan, Italy.
read more
Thursday, January 19, 2023
Cambrex has completed its acquisition of Snapdragon Chemistry, a US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
read more
Friday, December 06, 2019
Cambrex announced the completion of its previously announced sale to an affiliate of the Permira funds.
read more
Thursday, September 13, 2018
Cambrex has completed the acquisition of Halo Pharma, a dosage form CDMO located in Whippany, New Jersey and Mirabel, Québec, Canada, for approximately $425 million.
read more
Wednesday, January 02, 2019
Cambrex has completed the acquisition of Avista Pharma Solutions, a contract development, manufacturing, and testing organization, from Ampersand Capital Partners.
read more
Cambrex Corporation has announced the completion and validation of a $50 million state-of-the-art production and warehousing expansion at its cGMP Charles City, Iowa site. The investment in capacity and capabilities was made in reflection of strong ...
read more
Thursday, December 05, 2024
Cambrex, announced that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly's biotech collaborators.
read more
Wednesday, April 01, 2020
Cambrex announced Troy Player has been appointed as President, Early Stage Development and Testing (ESDT).
read more